Zolgensma denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for zolgensma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Deny Zolgensma for Medical Necessity

Zolgensma (onasemnogene abeparvovec) is a one-time gene replacement therapy for spinal muscular atrophy (SMA). UnitedHealthcare's medical-necessity denials for Zolgensma typically occur when the submitted documentation does not clearly establish that the patient meets every criterion set out in the insurer's coverage policy — often related to confirmed genetic diagnosis, disease type, functional status, age or weight range per the FDA label, or the absence of disqualifying factors.

Because Zolgensma is one of the most resource-intensive therapies available, payers apply close scrutiny to every prior authorization request. A medical-necessity denial does not mean the treatment is inappropriate — it means the insurer concluded the submitted record did not yet prove eligibility under their published criteria. A well-constructed appeal that maps every chart fact to every policy requirement has a meaningful chance of success.

## Your Appeal Rights

• Internal appeal: You have the right to submit a written internal appeal, typically within 180 days of the denial. Under ERISA §503, employer-plan members are entitled to a full-and-fair review and must be given access to all clinical criteria the insurer relied upon.
• External review (ACA §2719): After an adverse internal decision, you may request independent external review. The standard window is up to four months from the final internal denial. If the patient's condition is urgent or rapidly progressing, request an expedited external review (72-hour turnaround required).

## Documentation to Gather

1. Genetic confirmation — laboratory report confirming SMA diagnosis with SMN1 deletion/mutation and SMN2 copy number, signed and dated. 2. Disease type and staging — neurologist's documentation of SMA type, symptom onset timeline, and current functional status. 3. Motor function and pulmonary assessments — dated clinical assessments using standard motor scales and pulmonary function records as captured in the chart. 4. Prior treatment history — a complete log of any prior or current SMA-directed therapies, including dates, doses, and documented outcomes or reasons for transition. 5. Prescriber medical-necessity letter — a detailed letter from the treating pediatric neurologist explaining why Zolgensma is medically necessary for this specific patient, citing the FDA-approved prescribing information and applicable professional society guidelines. 6. Specialist consultation notes — records from any neuromuscular disease specialist or multidisciplinary SMA clinic supporting the treatment decision.

## Criteria-Mapping Structure

Download the current UnitedHealthcare coverage policy for Zolgensma and the FDA-approved prescribing label. For each listed criterion, document the corresponding chart evidence:

| Policy / Label Criterion | Chart Evidence with Date | |---|---| | Confirmed SMA genetic diagnosis | Genetic lab report, [date] | | SMA type and clinical presentation | Neurologist note, [date] | | Age / weight / functional status per label | Clinic visit record, [date] | | Absence of disqualifying conditions per label | Prescriber attestation, [date] | | Prescriber specialty requirement | Treating physician credentials |

Submit the criteria-mapping table as part of your appeal cover letter so the reviewer can follow your argument without searching through records. A complete, organized submission reduces the chance of a second denial on procedural grounds.